Through our highly experienced ADC Research & Development Team, we are focussed on driving innovation in ADC design to build a pipeline of class-leading ADCs for difficult-to-treat cancers.
We avoid dogma to drive innovation, aiming to design and deliver ADCs with tailored components for maximum impact. Our goal is to design the best ADC for any given target or tumor sub-type rather than ‘technology-driven ADCs’.
All our ADCs incorporate tumor-selective release & activation of payloads with mechanisms that are highly relevant for the target and tumor, thus optimizing anti-cancer efficacy and enhancing patient safety. Our clinical stage pipeline provides validation to this approach and underscores our deeper, next generation ADC portfolio combining novel targets and platforms.
Iksuda has developed a new protein alkylating payload class - ‘ProAlk’. With its tailored ADC-relevant properties and wide, cross tumor utility IKSUDA is now building a next-wave pipeline of ProAlk-ADCs.
Iksuda's approach
Every ADC needs careful and individual design consideration to achieve its optimal profile. ADC design expertise and an ability to learn from past experiences is necessary to understand the nuances of this modality for maximal probability of success.
Optimal ADC design requires informed innovation and solid background knowledge; combining suitably and synergistically optimized platforms for tailored profiles.
Iksuda has built a team of experts in ADC drug development and design. We have learned from the past and continue to innovate – we don’t let ADC dogma get in the way of progress.
Clinical programs validate our method for tumor-specific activation of payload to enhance TI. This enables the incorporation of novel targets and our new ProAlk payload in best- and first-in-class ADCs.
If you’re looking for an expert ADC development partner, access to innovative ADC technologies and guidance for designing and developing new ADCs, or licenses to class leading ADC programs, Iksuda is keen to hear from you.
Lead programs
I am thrilled to be working with Iksuda because of our commitment to lead the crowd, not follow it
ADC Design Principles
Building a successful ADC pipeline requires experience-based integration of multiple components to achieve a high probability of success.
Iksuda ensures the optimal delivery of the most appropriate payload MoA for any given target and tumor; all programs incorporate tumor-selective payload release & activation.
Although our programs are weighted towards monospecific antibodies, we work alongside partners to assess bi-specific conjugates which have strong technical rationale behind the choice of pairings and where the profile betters that of the comparative monospecific ADCs. Where we feel a conjugate to a known target can be improved by binder optimization, including internalization, binding selectivity or cross-reactivity profiles, we will generate or source suitable variants.
ADC Design Strategy
Building superior ADCs
Iksuda ADCs are designed for maximum anti-cancer impact and market leading TI, for patients that, today, have few effective treatment options.
Tumor Selective Payload Activation
Precision targeting of the optimal payload MOA
Iksuda incorporates highly advanced tumor-selective cleavable linkers in all its ADCs for improved safety.
Optimal Payload Choices
Exploring multiple payload series with known and novel mechanisms
After validating the glucuronide-driven payload delivery Introducing, Iksuda is now proud to introduce ProAlk, our first-in-class protein alkylating payload.
Stable Bioconjugation
Simple, scalable solutions to ADC instability
Stable bioconjugation is fundamental to ADC design. Iksuda uses proprietary and in-licensed technologies for the stable bioconjugation to wild-type or engineered antibodies.
Groundbreaking science delivered by expert teams
The quality of our people defines our business. Our people are given the freedom to innovate, alongside the guidance and support that comes with being part of a collaborative team.
